MERS Virus Treatment Effective In Testing

As Mersa Virus infections continue to pile up at an alarming rate, especially in Saudi Arabia, new research is gaining ground the idea that a combination of existing drugs may help some patients infec...
MERS Virus Treatment Effective In Testing
Written by Lacy Langley
  • As Mersa Virus infections continue to pile up at an alarming rate, especially in Saudi Arabia, new research is gaining ground the idea that a combination of existing drugs may help some patients infected with the new MERS coronavirus. Currently, there is no vaccine to help prevent the coronavirus and no drug specifically to treat and lessen damage caused by it in severe cases.

    The new research into the drug combo shows it helps reduce the severity of disease in macaque monkeys deliberately infected with MERS. Macaques given ribavirin and interferon alpha 2b after having been infected with the MERS coronavirus were less sick than infected animals that weren’t given the therapy. While the regimen was previously tested in kidney cells from monkeys, these findings are the first showing what happens when the drugs are used in living animals.Also, follow-up autopsies of the treated and untreated animals showed lower levels of virus in tissues and less lung damage in the treated animals.

    “Everything fit together towards suggesting that treatment definitely helps lead to a better outcome than the absence of treatment,” said Darryl Falzarano, a Canadian scientist who is the lead author of the study, published Sunday in the journal Nature Medicine.Falzarano is currently a visiting fellow at U.S. National Institute of Allergy and Infectious Diseases’ Rocky Mountain Laboratories in Hamilton, Mont, where the study is being conducted.

    When the MERS virus became well-known about a year ago, scientists decided they didn’t have time to go through the process of developing a new drug from scratch. Apparently, Persuading a pharmaceutical company the sales potential warrants production, pushing the new compound through clinical trials and securing regulatory approval adds tens of millions of dollars in costs and additional years to the process. So, scientists decided to start testing drugs we already have, alone and in combination. Interferon alpha 2b is a synthetic version of a protein made by the human immune system. Ribavirin is an antiviral drug used for infections like hepatitis C. It was also widely used during the 2003 SARS outbreak; MERS is from the same family of viruses as SARS.

    While ribavirin was a natural place to start for MERS, it’s not clear the drug was actually useful in treating SARS. The explosive start and short duration of the outbreak meant there was no time to conduct clinical trials looking at whether the patients who got the drug were more likely to survive. As both drugs have long been in use, there are no regulatory hurdles doctors would need to clear to try the combination in MERS patients. Still, that doesn’t mean they will rush to use the regimen.

    Unfortunately the macaque model, while very beneficial has some caveats that shouldn’t be overlooked, one of those being that, so far the only known animal model for laboratory work with the MERS virus is the macaque. They can be infected with the coronavirus, but the ensuing disease does not fully reflect what goes on in when humans contract the virus. The monkeys develop mild to moderate infections when exposed to MERS, but they do not get as extremely ill as many human cases do.

    “At the moment, this is as good as it gets,” Dr. Heinz Feldmann, chief of virology at the Rocky Mountain Labs and senior author of the paper, said of the animal model. “Our job is to provide options, and this is certainly one. Whether they consider this a good one or not, it’s up to the physicians.”

    “There are doctors who don’t have much problem using ribavirin and interferon (alpha 2b), and there are physicians that have all kinds of problems to use ribavirin and interferon,” said Feldmann, suggesting side-effects of the drugs may scare off some practitioners.

    The therapy has been tried in some cases in Saudi Arabia, the country’s deputy minister of health said via email. “We have used this combination regimen on a group of patients but it’s not routinely used in all patients,” Dr. Ziad Memish said. Because the treatment wasn’t started in the cases of the very ill until later in the course of the infections, Memish said that the outcome hasn’t been very positive.

    Another scientist working to identify drugs and develop a vaccine to use against MERS, Matt Friedman, praised the work outlined in the study, but said more research is needed to see whether this drug combination should be used, especially in severely ill patients. “I think as an initial study, it’s well done and it gives us a lot of information to start identifying what other experiments should be followed up with in future,” he said, adding,“The leap between that data and treating a person infected with MERS who has other co-morbidities — I think it needs to be studied further.”

    On Saturday the World Health Organization put the global count of MERS infections at 114 with 54 deaths. But since then Saudi authorities have announced eight additional cases, three of them fatal. That will push the global total to 122 cases and 57 deaths.

    Image via Wikipedia

    Get the WebProNews newsletter delivered to your inbox

    Get the free daily newsletter read by decision makers

    Advertise with Us

    Ready to get started?

    Get our media kit